MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

FORMAL RELEASE OF ONE-YEAR FOLLOW-UP RESULTS FROM THE EARLY FEASIBILITY STUDY OF ALTAVALVE™

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Director(s)**") of the Company (the "**Board**") is pleased to announce that the one-year follow-up results from the early feasibility study of AltaValve™, a transcatheter mitral valve replacement ("**TMVR**") medical device ("**AltaValve™**") independently developed by the Group's associated company, 4C Medical Technologies, Inc. ("**4C Medical**"), have been formally released.

This study was conducted across multiple centers in Europe, the United States and Japan, enrolling 30 patients who were all at high surgical risk and presented with symptomatic severe mitral regurgitation ("**MR**"). Among them, 13 patients were treated via a transapical approach, while 17 were treated via a transseptal approach. The one-year follow-up results demonstrated a technical success rate of 97%, with complete elimination of MR in all patients. The mitral valve transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-procedure, indicating significant improvement in cardiac hemodynamics. In terms of safety, the all-cause mortality rate at one year was 17% in the transapical group and 7% in the transseptal group, with 0 cardiogenic mortality reported. No adverse events such as stroke, new-onset atrial fibrillation, or mitral valve reintervention occurred in the entire cohort. In addition, 96% of patients achieved promotion of New York Heart Association (NYHA) Class to I or II functional status at one year, indicating substantial improvement in quality of life.

AltaValve™ has been granted two Breakthrough Device designations by the U.S. Food and Drug Administration (the "**FDA**") in 2024 and is currently undergoing pivotal clinical studies in Europe and the United States under an FDA-approved Investigational Device Exemption (IDE).

About AltaValve™

As the world's first atrial-anchored TMVR device, AltaValve™ is also the only fully retrievable, low-profile transseptal TMVR system. It features a unique supra-annular design that positions the prosthetic valve above the native mitral valve, minimizing the risk of left ventricular outflow tract (LVOT) obstruction while preserving native valve function. The device is adaptable to a wide range of mitral valve annular sizes, making it suitable for a broad patient population with MR. Moreover, the system is fully repositionable and retrievable, with a straightforward implantation process that significantly shortens the learning curve for physicians.

About 4C Medical

4C Medical is a company incorporated under the laws of Delaware, focusing on the development of innovative medical devices for the treatment of structural heart diseases, including mitral and tricuspid regurgitation. The Group has made several rounds of investment in 4C Medical and holds exclusive commercial rights for AltaValve™ in Mainland China, Hong Kong, Macau and Taiwan. In 2025, the company completed a Series D financing of USD175 million to accelerate global clinical trials and commercialization.

The Company cannot guarantee that AltaValve™ will be ultimately successfully commercialized. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, December 30, 2025

As at the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.